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a  b  s  t  r  a  c  t
Aim:  This  paper  aims  to identify  factors  that  influence  the  psychological  wellbeing  of  patients  newly
diagnosed  with  localized  breast  cancer.
Background:  Psychological  wellbeing  plays  a  significant  part  in the personal  experience  of  patients  during
their cancer  journey.  However,  despite  progress  in treatments  and  outcomes  in breast  cancer,  psychoso-
cial  services  and emotional  support  of  cancer  patients  have  been  given  less  attention.
Materials  and  methods:  Data  were  collected  through  a retrospective  review  of  274  charts  of  women  diag-
nosed  with  breast  cancer  between  2012  and  2017  that received  care  in a single  cancer  center.  Disease
specific  parameters,  social  and  demographic  variables,  and  Edmonton  Symptom  Assessment  System
(ESAS)  scores  were  extracted  from  the  patient  charts.
Results:  Self-reported  scores  of  psychological-related  symptoms  were  low  (suggesting  no  or  minimal
psychological  distress)  at  baseline  and  remained  low  in  the majority  of patients  with  breast  cancer.
Pain,  depression,  anxiety  and  wellbeing  scores  of 0–2 were  observed  in 78.5%,  81.4%,  63.5%  and  70.1%
of  patients,  respectively.  Higher  scores  of anxiety  at  baseline  were  observed  in patients  with  physical
restrictions  on  the  Eastern  Cooperative  Oncology  Group  performance  status  (ECOG  PS)  (14.9%),  current
smoking  (20.5%)  and  history  of  mental  illness  (19.1%).  Increasing  scores  for pain  were  observed  in older
patients  during  treatment  as  compared  to  baseline.  Mastectomy  was  associated  with  increased  scores  for
wellbeing (worsening  wellbeing)  as compared  to lumpectomy.  Of the  patients  with  a  history  of  mental
illness  (17.3%),  19.1%  had  more  often  increased  scores  for anxiety.
Conclusions:  The  findings  highlight  patients  that  may  benefit  from  additional  social  and  psychological
supports  at  diagnosis  and  while  undergoing  treatment.






Despite advances in treatment options and outcomes for
patients with breast cancer, psychosocial services and supports
have lagged behind.1 Treatment-related side effects range from
side effects that impact quality of life and those that affect fam-
ily members and friends of patients.1 Three side effects due to
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nd fatigue.2 Moreover, women who undergo mastectomy report
ore anxiety and depression in comparison to women who have
reast conserving surgery.3 Depression is shown to be more preva-
ent among older and single patients while anxiety is higher in
atients residing in rural regions. In another study, women under-
oing treatment for anxiety and depression, as well as those with a
edical history of anxiety and depression are more likely to have
igher symptom severity scores in these domains.4
The Edmonton Symptom Assessment System (ESAS) scale5,6 is
 validated symptom assessment tool used to identify and mon-
tor nine symptoms that are commonly experienced by patients
ith cancer: pain, tiredness, nausea, depression, anxiety, drowsi-
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the tool, patients are asked to rate each symptom using a Likert
scale from 0 to 10 where 0 indicates the absence of symp-
toms and 10 indicates the highest severity. The ESAS tool and
the Functional Assessment of Cancer Therapy- Breast (FACT-B)
self-administered questionnaires are commonly used to perform
psychological assessments in patients with breast cancer. These
tools have been used to examine quality of life and symptom bur-
den in patients with breast cancer that have either undergone
mastectomy or lumpectomy.7 The type of breast cancer surgery
was also the focus of another study that used the Hospital Anxi-
ety and Depression Scale (HADS) and Beck Depression Inventory
(BDI).3 Several studies have used the ESAS tool to compare cohorts
of patients receiving breast cancer treatment to derive informa-
tion on their symptomatology as well as on the effect of treatments
on quality of life. For example, in patients with bony metastases
receiving bisphosphonates, ESAS scores for wellbeing were higher
compared to patients not receiving these drugs.8
Studies in diverse settings have highlighted family history of
cancer, lower education, as well as low income and financial con-
straints as some of the key predictors of a low quality of life score
in patients with breast cancer.9,10 In the young African Ameri-
can population of breast cancer survivors, personal relationships,
anxiety/depression and cognitive dysfunctions were identified as
factors associated with psychological wellbeing.10 Hence, psycho-
logical wellbeing has been shown to vary depending on factors such
as type of breast cancer, specific treatments, demographic vari-
ables and medical history. Since increased prevalence of anxiety
and depression has been seen at diagnosis of breast cancer, the
integration of psychosocial care into routine cancer care cannot be
disregarded.1
In summation, psychological factors are important for the well-
being of patients with breast cancer and long-term outcomes of
breast cancer.
2. Aim
This study examines factors that influence psychological well-
being of patients newly diagnosed with localized breast cancer. We
analyzed these variables in order to inform both the prioritization
of resources and targeted interventions to patient cohorts with the
greatest need. Supporting the psychological wellbeing of patients
with breast cancer, in addition to their quality of life might improve
cancer outcomes by optimization of adherence to therapies. For
the purpose of this study, psychological wellbeing was  operational-
ized as an aggregate of the individual pain, depression, anxiety and
wellbeing scores on the ESAS scale. The proportion of patients with
different psychological states as depicted by ESAS scores were mea-
sured. In addition, disease, demographic and social variables that
influence psychological wellbeing in patients with breast cancer
were determined. Finally, comparisons of psychological compo-
nents on the ESAS before and during treatment were performed to
identify patient groups with worsening self-reported psychological
measures.
3. Methods
Data were collected through a retrospective review of 274 charts
of women diagnosed with breast cancer between 2012 and 2017.
Data were collected using patients’ electronic medical records and
paper charts. The following variables were captured: age and year of
diagnosis, surgical date, TNM (tumor, nodes and metastases) classi-
fication, pathological stage (determined by TNM), grade of tumor,
histology, type of surgery (lumpectomy or mastectomy), axillary
node dissection or sentinel node biopsy, and treatment types (radi-
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herapy). Other demographics of interest, social and medical his-
ory that were recorded and analyzed were marital status, living
rrangement (alone versus with family or in an assisted living facil-
ty), religious practices, tobacco use, alcohol use, and history of
ental illness. Patients with missing baseline ESAS scores were
xcluded.
At initial evaluation, patients with breast cancer were invited
o complete a questionnaire which collected information about
ociodemographic characteristics and past medical and social his-
ory. Patients were asked to complete the ESAS tool at baseline
nd at each follow-up visit. Among the nine items that constitute
he ESAS symptomatic evaluations, each rated on a 0–10 Likert
cale, the four relating directly or indirectly to psychological well-
eing (aggregate pain, depression, anxiety and wellbeing symptom
cores), were extracted and recorded in a database specifically cre-
ted for the purpose of this study. For each patient, scores from
 baseline ESAS (ESAS1) and the first available ESAS from 2 to 12
onths later (ESAS2) were assessed. The primary endpoint was
dentifying associations of individual and aggregate psychological
ellbeing scores (aggregate pain, depression, anxiety and well-
eing symptom scores) with baseline characteristics of patients
nd their disease. The individual and aggregate wellbeing scores
t baseline and during treatment were compared and correlations
ere also derived.
Statistical analysis was performed using an online statistical
oftware program. The analysis used a combination of descriptive
nd categorical statistics to identify significant differences between
reatment groups.
The sample size of 274 patients in the cohort allowed for the
dentification of statistically significant and clinically meaningful
ifferences at a confidence interval of 90%. Chi-square tests were
sed to identify any significant differences between treatment
roups. The paired t-test was  conducted to compare pre-treatment
nd on-treatment ESAS scores of the various groups. The Pearson’s
 correlation test was used in correlation evaluations to determine
he association between the continuous variables. The significance
evel was  set at p < 0.05.
. Results
Table 1 shows the patient age, disease/treatment character-
stics and the respective aggregate baseline ESAS (ESAS1) scores
0–6 versus 7–10). Of the 274 patients in the series, 52.6% were 65
ears old or younger and 15% were younger than age 50 (Table 1).
5% had Stage I disease, 36.6% had Stage II disease and 8.4% had
ocally advanced, Stage III breast cancer. The majority of patients
65.9%) had a lumpectomy and 61.5% had grade 1 or grade 2 can-
ers. 86% of the patients received hormonal therapy (HTx), 66.8%
eceived adjuvant radiotherapy (RTx) and 40.1% received adjuvant
hemotherapy.
Table 2 presents the social and functional status as well as habits
f patients and the respective ESAS1 scores. About 70% of patients
ere married or in common-law relationships while 30% were sin-
le, divorced or widowed. 73.2% self-identified as non-religious,
4.7% were current smokers and 60% reported current regular alco-
ol use of any amount. The ECOG PS (Eastern Co-operative Oncology
roup Performance Status) of 62.6% of patients was 0 (asymp-
omatic) and 17.3% of patients had a history of mental illness.
Table 3 shows the number of patients with self-reported ESAS1
nd during follow-up (ESAS2) scores for pain, depression, anxi-
ty and wellbeing. Most patients in the cohort self-reported no or
inimal pain, depression and anxiety and a strong sense of global
ellbeing in the respective symptom (ESAS scores of 0–3) both
t baseline, and during treatment and follow-up (Table 3). Mean





















Associations of patients and disease/ treatment characteristics with baseline ESAS (ESAS1) scores (0–6 versus 7–10). Lymph node data were recorded in 127 pts of the cohort. Six patients had in situ carcinomas and for 6 pts no
staging  data were available. SNB: Sentinel Node Biopsy, AND: Axillary Node Dissection, RTx: Radiotherapy, HTx: Hormonal therapy.
All (%) ESAS pain (%) ESAS depression (%) ESAS anxiety (%) ESAS well-being (%)
Low (0−6) High (7−10) p Low (0−6) High (7−10) p Low (0−6) High (7−10) p Feel well (0−6) Less well (7−10) p
Age ≤65 144 (52.6) 139 (96.5) 5 (3.5) 0.12 137 (95.1) 7 (4.9) 0.68 128 (88.9) 16 (11.1) 0.22 136 (94.4) 8 (5.6) 0.95
Age  >65 130 (47.4) 120 (92.3) 10 (7.7) 125 (96.2) 5 (3.8) 121 (93.1) 9 (6.9) 123 (94.6) 7 (5.4)
Age  ≤50 41 (15.0) 40 (97.6) 1 (2.4) 0.35 39 (95.1) 2 (4.9) 0.86 36 (87.8) 5 (2.2) 0.45 38 (92.7) 3 (7.3) 0.57
Age  >50 233 (85.0) 219 (94.0) 14 (6.0) 223 (95.7) 10 (4.3) 213 (91.4) 20 (8.6) 221 (94.8) 12 (5.2)
Lumpectomy 178 (65.9) 170 (95.5) 8 (4.5) 0.47 171 (96.1) 7 (3.9) 0.87 162 (91.0) 16 (9.0) 0.70 169 (94.9) 9 (5.1) 0.89
Mastectomy 92 (34.1) 86 (93.5) 6 (6.5) 88 (95.6) 4 (4.4) 85 (92.4) 7 (7.6) 87 (94.6) 5 (5.4)
SNB  74 (58.3) 71 (95.9) 3 (4.1) 0.67 71 (95.9) 3 (4.1) 0.49 71 (95.9) 3 (4.1) 0.67 71 (95.9) 3 (4.1) 0.93
AND  53 (41.7) 50 (94.3) 3 (5.7) 52 (98.1) 1 (1.9) 50 (94.3) 3 (5.7) 51 (96.2) 2 (3.8)
Stage  I 144 (55.0) 139 (96.5) 5 (3.5) 0.15 140 (97.2) 4 (2.8) 0.26 133 (92.4) 11 (7.6) 0.31 138 (95.8) 6 (4.2) 0.46
Stage  II 96 (36.6) 87 (90.6) 9 (9.4) 89 (92.7) 7 (7.3) 84 (87.5) 12 (12.5) 89 (92.7) 7 (7.3)
Stage  III 22 (8.4) 21 (95.5) 1 (4.5) 21 (95.5) 1 (4.5) 22 (100) 0 20 (90.9) 2 (9.1)
Grade  I/II 161 (61.5) 154 (95.7) 7 (4.3) 0.36 155 (96.3) 6 (3.7) 0.63 145 (90.1) 16 (9.9) 0.40 155 (96.3) 6 (3.7) 0.14
Grade  III 101 (38.5) 94 (93.1) 7 (6.9) 96 (95.0) 5 (5.0) 94 (93.1) 7 (6.9) 93 (92.1) 8 (7.9)
No  RTx 91 (33.2) 83 (91.2) 8 (8.8) 0.08 88 (96.7) 3 (3.3) 0.53 84 (92.3) 7 (7.7) 0.56 85 (93.4) 6 (6.6) 0.56
RTx  183 (66.8) 176 (96.2) 7 (3.8) 174 (95.1) 9 (4.9) 165 (90.2) 18 (9.8) 174 (95.1) 9 (4.9)
No  Chemotherapy 164 (59.9) 153 (93.3) 11 (6.7) 0.27 158 (96.3) 6 (3.7) 0.47 150 (91.5) 14 (8.5) 0.68 157 (95.7) 7 (4.3) 0.28
Chemotherapy 110 (40.1) 106 (96.4) 4 (3.6) 104 (94.5) 6 (5.5) 99 (90.0) 11 (10.0) 102 (92.7) 8 (7.3)
No  Hormonal Therapy 38 (14.0) 38 (100) 0 0.34 38 (100) 0 0.48 36 (94.7) 2 (5.3) 0.36 36 (94.7) 2 (5.3) 0.94
Hormonal Therapy 234 (86.0) 219 (93.6) 15 (6.4) 222 (94.9) 12 (5.1) 211 (90.2) 23 (9.8) 221 (94.4) 13 (5.6)
Table 2
Social factors, habits and performance status and baseline ESAS (ESAS1) scores (0–6 versus 7–10) of the patients in the cohort. ETOH: Alcohol use, ECOG: Eastern Co-operative Oncology Group Performance Status, Mental History:
History  of mental illness.
All (%) ESAS pain (%) ESAS depression (%) ESAS anxiety (%) ESAS well-being (%)
Low (0−6) High (7−10) p Low (0−6) High (7−10) p Low (0−6) High (7−10) p Feel well (0−6) Less well (7−10) p
Married/ Common Low 180 (69.2) 174 (96.7) 6 (3.3) 0.02 175 (97.2) 5 (2.8) 0.08 165 (91.7) 15 (8.3) 0.66 169 (93.9) 11 (6.1) 0.72
Single/  Divorced/Widow 80 (30.8) 72 (90.0) 8 (10.0) 74 (92.5) 6 (7.5) 72 (90.0) 8 (10.0) 76 (95.0) 4 (5.0)
Religious 63 (26.8) 60 (95.2) 3 (4.8) 0.88 61 (96.8) 2 (3.2) 0.61 58 (92.1) 5 (7.9) 0.74 61 (96.8) 2 (3.2) 0.50
Not  Religious 172 (73.2) 163 (94.8) 9 (5.2) 164 (95.3) 8 (4.7) 156 (90.7) 16 (9.3) 163 (94.8) 9 (5.2)
Current  Smoker 39 (14.7) 36 (92.3) 3 (7.7) 0.55 35 (89.7) 4 (10.3) 0.06 31 (79.5) 8 (20.5) 0.01 36 (92.3) 3 (7.7) 0.55
Not  Current Smoker 226 (85.3) 214 (94.7) 12 (5.3) 218 (96.5) 8 (3.5) 209 (92.5) 17 (7.5) 214 (94.7) 12 (5.3)
ETOH  153 (60.0) 147 (96.1) 6 (3.9) 0.29 146 (95.4) 7 (4.6) 0.90 138 (90.2) 15 (9.8) 1.0 146 (95.4) 7 (4.6) 0.27
No  ETOH 102 (40.0) 95 (93.1) 7 (6.9) 97 (95.1) 5 (4.9) 92 (90.2) 10 (9.8) 94 (92.2) 8 (7.8)
ECOG  0 124 (62.6) 119 (96.0) 5 (4.0) 0.65 120 (96.8) 4 (3.2) 0.45 117 (94.4) 7 (5.6) 0.02 121 (97.6) 3 (2.4) 0.13
ECOG  >0 74 (37.4) 70 (94.6) 4 (5.4) 70 (94.6) 4 (5.4) 63 (85.1) 11 (14.9) 69 (93.2) 5 (6.8)
Mental  History 47 (17.3) 43 (91.5) 4 (8.5) 0.32 43 (915) 4 (8.5) 0.13 38 (80.9) 9 (19.1) 0.009 42 (89.4) 5 (10.6) 0.06
No  Mental History 224 (82.7) 213 (95.1) 11 (4.9) 216 (96.4) 8 (3.6) 208 (92.9) 16 (7.1) 215 (96.0) 9 (4.0)
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(SEM = 0.12) for depression, 2.18 (SEM = 0.15) for anxiety and 1.83
(SEM = 0.13) for wellbeing.
ESAS1 scores for pain, depression, anxiety and wellbeing cate-
gorized as low (ESAS scores of 0–6) or high (ESAS scores of 7–10)
were not associated with any tumor or treatment characteristic
(p > 0.05) (Table 1). Among social factors, marital status was associ-
ated with low baseline self-reported pain (p = 0.02) (Table 2). Three
times more patients (10%), who were single, divorced or widowed,
reported pain (ESAS scores of 7–10) as compared to 3.3% of patients
that were married or in common-law relationships. In addition, sig-
nificantly more patients that were current smokers, symptomatic
from cancer (ECOG PS 1–2) and that had a history of mental ill-
ness, compared to other characteristics, self-reported high ESAS1
(ESAS scores of 7–10) for anxiety (Table 2). Current smoking status
and presence of symptoms (ECOG PS 1–2) were also significantly
associated with high ESAS1 scores in any (one or more) of the four
symptoms (p = 0.04) (Table 4). History of mental illness was asso-
ciated with high ESAS scores during treatment (ESAS2) in any (one
or more) of the four symptoms (p < 0.01) (Table 5).
Age (>65 years) and cancer of lower grade (grade I or II) were
more commonly associated with an increase of three or more points
between the two ESAS scores for pain. Similarly, mastectomy was
more commonly associated with an increase between the ESAS
scores for wellbeing. This denoted a worsening of self-reported
wellbeing in patients that had undergone a mastectomy compared
to patients that had undergone a lumpectomy. Patients with a pre-
vious history of mental illness were at higher risk to self-report
increased anxiety (p < 0.01).
Overall, mean ESAS scores during follow-up (ESAS2) were
very similar to ESAS1 scores (Table 3). Mean ESAS2 scores were
1.48 (SEM = 0.14) for pain, 1.23 (SEM = 0.13) for depression, 1.62
(SEM = 0.13) for anxiety and 1.87 (SEM = 0.13) for wellbeing. Com-
parisons of the mean ESAS scores at baseline and during treatment
showed a statistically significant decrease from 2.18 to 1.62 (paired
t = 3.64, p < 0.01) in anxiety while the means of the three other
symptoms were not significantly different. The two  ESAS scores of
each patient were weakly correlated (Pearson’s R = 0.307) for pain
and weak to moderately correlated (both with a Pearson’s R = 0.39)
for the anxiety and wellbeing symptoms. The two  ESAS scores
were moderately correlated (Pearson’s R = 0.51) for depression. The
cumulative scores of the four symptoms also showed a moderate
correlation between the two time points (Pearson’s R = 0.50).
5. Discussion
While advances in therapeutic options for patients undergoing
breast cancer treatment continue to evolve, psychological support
remains an area that requires continuous attention.11 Breast can-
cer diagnosis and its subsequent treatment can be both physically
and emotionally distressing.12 In order to better focus resources for
these supports, identification of patients undergoing breast cancer
treatment with greater needs is of importance and would help tar-
get the most vulnerable patients. Studies have attempted to address
the question of identifying cancer patients that are psychologically
more vulnerable at an early point during their cancer journey, and
these findings contribute to this area of research.
We found low self-reported ESAS scores in all ESAS symptoms
examined in the majority of patients with early breast cancer, sug-
gesting low psychological distress. During treatment, ESAS scores
tended to remain stable, except for anxiety scores that decreased,
suggesting that as time passed from diagnosis and as treatment
plans were executed, patient anxiety was reduced. The existing evi-
dence shows that psychological status may  be a factor contributing
not only to the wellbeing of patients with breast cancer but also a
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lay a role in patient adherence to treatments which may  affect dis-
ase outcomes.13 This aligns with the findings of Hui et al14 who
eported depression together with stage and hormonal status as
redictors of Overall Survival (OS).
Only 3.3 % of patients that were married or common-law
eported high baseline pain (ESAS scores of 7–10), indicating that
arital status can be a protective factor from breast cancer symp-
om burden. Similarly, Martinez et al.15 and, Zhai et al.16 found
etter prognosis and survival outcomes in women that were mar-
ied at the time of diagnosis as compared to their non-married (i.e.,
ivorced, separated or widowed) counterparts. Greater financial
esources and psychosocial support are some underlying factors
ssociated with higher overall survival in married patients at the
ime of breast cancer diagnosis.16
Patients who had undergone mastectomy had more often
ncreasing scores in wellbeing, indicating worsening wellbeing,
ompared with patients that had undergone lumpectomy. The
ndings were in concordance with other studies which reported
ignificantly higher scores in several domains including pain,
nxiety and depression as compared to those patients who had
ndergone lumpectomy.3,7
Higher ECOG PS, current smoking and history of mental illness
ere associated with higher scores in anxiety at the beginning of
djuvant cancer treatment. Patients with a history of mental illness
ad more often increasing scores in anxiety during treatment com-
ared to baseline self-reported anxiety. Other studies17,18 show
ncreased prevalence of clinically relevant anxiety and depression
ymptoms in patients that experience restricted daily activities due
o acute breast cancer treatment side effects. Additionally, patients
hat have comorbid conditions at diagnosis of their breast cancer
re confronted with challenges in adhering to treatment regimens,
hich can lead to onset of anxiety disorders.19
Fatigue is a commonly reported side effect of anti-cancer
reatments.1 The etiology of fatigue consists of a psychological com-
onent which contributes to depression and impaired activities of
aily living (measured through ECOG PS) among others.1 Though
ur study did not examine fatigue as a marker for psychological
ellbeing among patients with breast cancer, the higher scores for
COG PS in our study can be associated with fatigue or fatigue-
elated side effects of breast cancer treatment.
Results from this study showed that women’s age (>65) was
lso associated with an increase between the two  ESAS scores for
ain. Various age-related factors may  increase the stress levels of
lder women making it difficult for them to cope with diagnosis and
reatment for breast cancer.2 The evidence of psychosocial inter-
entions and their impact on the wellbeing of older patients with
reast cancer has been weak. Durá-Ferrandis et al20 state that the
resence of tangible social support during diagnosis and treatment
as the potential to reduce physical and cognitive deterioration
n older breast cancer survivors. In contrast, Villani et al. report
hat psychological interventions designed to reduce anxiety seem
o have decreased effectiveness in patients with breast cancer over
he age of 60. Given the increase in ESAS scores for pain in older
omen with breast cancer, increased surveillance of these cohorts
or adverse symptom burden during breast cancer treatment is
ecommended.
The strengths of the study include the homogeneity of the pop-
lation of newly diagnosed early breast cancer, the comparatively
arge size and the contemporary treatments used.
Since the study design was retrospective and it relied entirely
n a questionnaire to assess psychological wellbeing, the relation-
hips observed among variables cannot explain causation. Thus,
ome observed associations, such as the basal line ESAS scores and
tage may  be fortuitous. Moreover, some data were missing, espe-
ially in the scores during follow-up. This may  have introduced
nformation bias as patients with worsening status may  have been
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Table  3
Number of patients with each baseline (ESAS1) and during follow-up (ESAS2), scores (ESAS1 n = 274, ESAS2 n = 266).
ESAS value Pain1 Pain2 Depression1 Depression2 Anxiety1 Anxiety2 Well being1 Well being2
0 146 150 176 165 100 129 112 103
1  40 32 24 29 34 32 38 44
2  29 24 23 17 40 33 42 39
3  19 16 11 15 31 22 25 21
4  13 9 7 11 24 17 11 16
5  8 8 17 15 10 14 22 27
6  4 12 4 5 10 10 9 6
7  9 6 4 3 8 5 10 4
8  4 5 5 5 15 3 5 5
9  1 3 1 1 0 0 0 0
10  1 1 2 0 2 1 0 1
Table 4
Comparison of the group of patients with any of the four baseline ESAS (ESAS1) scales above 6 (any >6) with the group having all four ESAS1 scales of interest below 7 (all<
7).
ESAS total (%) ESAS total (%)
All <7 Any >6 p All <7 Any >6 p
Age ≤65 144 (52.6) 118 (81.9) 26 (18.1) 0.44 Married/ Common Low 180 (69.2) 154 (85.6) 26 (14.4) 0.26
Age  >65 130 (47.4) 111 (85.4) 19 (14.6) Single/ Divorced/Widow 80 (30.8) 64 (80.0) 16 (20.0)
Age  ≤50 41 (15.0) 34 (82.9) 7 (17.1) 0.90 Religious 63 (26.8) 52 (82.5) 11 (17.5) 0.74
Age  >50 233 (85.0) 195 (83.7) 38 (16.3) Not Religious 172 (73.2) 145 (84.3) 27 (15.7)
Lumpectomy 178 (65.9) 151 (84.8) 27 (15.2) 0.63 Current Smoker 39 (14.7) 28 (71.8) 11 (28.2) 0.04
Mastectomy 92 (34.1) 76 (82.6) 16 (17.4) Not Current Smoker 226 (85.3) 192 (85.0) 34 (15.0)
Stage  I 144 (55.0) 127 (88.2) 17 (11.8) 0.016 ETOH 153 (60.0) 130 (85.0) 23 (15.0) 0.33
Stage  II 96 (36.6) 72 (75.0) 24 (25.0) No ETOH 102 (40.0) 82 (80.4) 20 (19.4)
Stage  III 22 (8.4) 20 (90.9) 2 (9.1)
Grade I/II 161 (61.4) 135 (83.8) 26 (16.2) 0.88 ECOG 0 124 (62.6) 112 (90.3) 12 (9.7) 0.005
Grade III 101 (38.6) 84 (83.2) 17 (16.8) ECOG >0 74 (37.4) 56 (75.7) 18 (24.3)
No  Radiation Therapy 91 (33.2) 75 (82.4) 16 (17.6) 0.71 Mental History 47 (17.3) 35 (74.5) 12 (25.5) 0.057
Radiation Therapy 183 (66.8) 154 (84.2) 29 (15.8) No Mental History 224 (82.7) 192 (85.7) 32 (14.3)
No  Chemotherapy 164 (59.9) 139 (84.8) 25 (15.2) 0.51
Chemotherapy 110 (40.1) 90 (81.8) 20 (18.2)
No Hormonal Therapy 38 (14.0) 34 (89.5) 4 (10.5) 0.28
Hormonal Therapy 234 (86.0) 193 (82.5) 41 (17.5)
Bold values signifies the values are statistically significant.
Table 5
Comparison of the group of patients with any of the four ESAS scales during follow-up (ESAS2) above 6 (any >6) with the group having all four ESAS2 scales of interest below
7  (all< 7).
ESAS total (%) ESAS total (%)
All <7 Any >6 p All <7 Any >6 p
Age ≤65 142 (53.4) 125 (88.0) 17 (12.0) 0.70 Married/ Common Low 178 (70.1) 160 (89.9) 18 (10.1) 0.47
Age  >65 124 (46.6) 111 (89.5) 13 (10.5) Single/ Divorced/Widow 76 (29.9) 66 (86.8) 10 (13.2)
Age  ≤50 41 (15.4) 37 (90.2) 4 (9.8) 0.73 Religious 61 (26.5) 53 (86.9) 8 (13.1) 0.51
Age  >50 225 (84.6) 199 (88.4) 26 (11.6) Not Religious 169 (73.5) 152 (89.9) 17 (10.1)
Lumpectomy 174 (65.9) 156 (89.7) 18 (10.3) 0.64 Current Smoker 37 (14.3) 31 (83.8) 6 (16.2) 0.30
Mastectomy 90 (34.1) 79 (87.8) 11 (12.2) Not Current Smoker 221 (85.7) 198 (89.6) 23 (10.4)
Stage  I 141 (55.3) 128 (90.8) 13 (9.2) 0.30 ETOH 150 (60.5) 135 (90.0) 15 (10.0) 0.30
Stage  II 92 (36.1) 79 (85.9) 13 (14.1) No ETOH 98 (39.5) 84 (85.7) 14 (14.3)
Stage  III 22 (8.6) 21 (95.5) 1 (4.5)
Grade I/II 158 (61.7) 138 (87.3) 20 (12.7) 0.39 ECOG 0 121 (62.4) 108 (89.3) 13 (10.7) 0.16
Grade III 98 (38.3) 89 (90.8) 9 (9.2) ECOG >0 73 (37.6) 60 (82.2) 13 (17.8)
No  Radiation Therapy 87 (32.7) 79 (90.8) 8 (9.8) 0.45 Mental History 45 (17.0) 34 (75.6) 11 (24.4) 0.002
Radiation Therapy 179 (67.3) 157 (87.7) 22 (12.3) No Mental History 219 (83.0) 200 (91.3) 19 (8.7)
No  Chemotherapy 157 (59.0) 138 (87.9) 19 (12.1) 0.61
Chemotherapy 109 (41.0) 98 (89.9) 11 (10.1)
No Hormonal Therapy 37 (14.0) 36 (97.3) 1 (2.7) 0.08
6
e
Hormonal Therapy 227 (86.0) 199 (87.7) 28 (12.3)
Bold values signifies the values are statistically significant.
more prone to not complete the questionnaire. Selection bias could
stem from the fact that patients with missing ESAS1 scores in the
record were not eligible for inclusion in the study. Confounding bias
might have occurred because the type of questionnaire employed
does not inform underlying causes of the symptoms which may






The findings of this study may  identify the needs of differ-
nt cohorts of patients with breast cancer and pinpoint specific
ubsets of patients who  would benefit from additional support
hen undergoing breast cancer treatment. These include breast
ancer patients with a history of mental illness, current smok-
L. DeMiglio et al. 
ers and patients with decreased ECOG performance status. These
findings may  be used to inform the design and implementation
of focused interventional support programs addressing individ-
ual psychosocial needs. Future prospective qualitative research
involving patients directly may  inform specific areas of need as
well as the design and implementation of local and global support
programs.
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